Quarterly report pursuant to Section 13 or 15(d)

Reverse Recapitalization - Effect on Cash Flows and Equity (Details)

v3.22.2.2
Reverse Recapitalization - Effect on Cash Flows and Equity (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jun. 30, 2021
Sep. 30, 2021
Reverse Recapitalization    
Cash - BRPA trust and cash, net of redemptions   $ 4,363
Cash - PIPE financing, net of transaction costs   8,100
Less: transaction costs and advisory fees allocated to NRXP equity   (1,413)
Effect of merger on cash flows, net of redemption and transaction costs   $ 11,050
Cash - BRPA trust and cash effect on equity, net of redemptions $ 4,363  
Effect on equity from Non-cash net working capital assumed from BRPA (962)  
Less: notes payable assumed from BRPA (1,100)  
Less: fair value of assumed Placement Warrants (1,984)  
Less: fair value of legacy NeuroRx Warrants (38,220)  
Less: fair value of Earnout Cash (25,520)  
Less: transaction costs and advisory fees allocated to NRXP equity (1,413)  
Effect of Merger and recapitalization, net of redemptions and issuance costs $ (64,836)